NFKB1 and cancer: Furthermore, the combination of TQ (40 μM) and cisplatin with an NF-κB inhibitor (PDTC) led to enhanced cancer cell growth inhibition, underscoring the chemosensitizing effect of TQ via NF-κB inhibition.